Therapeutic approach to patients with familial Mediterranean fever-related amyloidosis resistant to colchicine

Clinical and Experimental Rheumatology

Volumn 30, Issue SUPPL.72, 2012, Pages

  Korkmaz, Cengiz ^a  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

Amyloidosis; Colchicine; Familial Mediterranean fever

Indexed keywords

AMYLOID; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; CHLORAMBUCIL; COLCHICINE; CREATININE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; GLYCOSAMINOGLYCAN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 6; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON ALPHA2A; PLACEBO; PREDNISOLONE; SERUM AMYLOID P; STEROID; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL PRODUCT;

AMYLOIDOSIS; ARTHRITIS; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG TOLERABILITY; FAMILIAL MEDITERRANEAN FEVER; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; MYALGIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEINURIA; REVIEW; RISK FACTOR; TREATMENT OUTCOME; VASCULITIS; CHRONIC KIDNEY FAILURE; DRUG RESISTANCE; NEPHROTIC SYNDROME;

AMYLOIDOSIS; BIOLOGICAL AGENTS; COLCHICINE; DISEASE PROGRESSION; DRUG RESISTANCE; FAMILIAL MEDITERRANEAN FEVER; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; NEPHROTIC SYNDROME;

EID: 84873258448     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (38)

1. GOLDFINGER SE: Colchicine for familial Mediterranean fever. N Engl J Med 1972;287:1302.
2. OZKAN E, OKUR O, EKMEKCI A, OZCAN R, TAG T: A new approach to the treatment of periodic fever. Med Bull Istanbul 1972;5:44-49.
3. CERQUAGLIA C, DIACO M, NUCERA G, LA REGINA M, MONTALTO M, MANNA R: Pharmacological and clinical basis of treatment of Familial Mediterranean Fever (FMF) with colchicine or analogues: an update. Curr Drug Targets Inflamm Allergy 2005;4:117-124.
4. LIDAR M, KEDEM R, LANGEVITZ P, PRAS M, LIVNEH A: Intravenous colchicine for treatment of patients with familial Mediterranean fever unresponsive to oral colchicine. J. Rheumatol 2003;30:2620-2623.
5. OZGOCMEN S, OZCAKAR L, ARDICOGLU O, KOCAKOC E, KAYA A, KIRIS A: familial Mediterranean fever responds well to infliximab: single case experience. Clin Rheumatol 2006;25:83-87.
6. MEINZER U, QUARTIER P, ALEXANDRA JF, HENTGEN V, RETORNAZ F, KONé-PAUT I: Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature. Semin Arthritis Rheum 2011;41:265-271.
7. SEYAHI E, OZDOGAN H, Çelik S et al.: Treatment options in colchicine resistant familial Mediterranean fever patients: thalidomide and etanercept as adjunctive agents. Clin Exp Rheumatol 2006;24(Suppl. 42):S99-S103.
8. AKAR S, YüKSEL F, TUNCA M et al.: Familial Mediterranean fever: risk factors, causes of death, and prognosis in the colchicine era. Medicine (Baltimore) 2012;91:131-136.
9. ZEMER D, PRAS M, SOHAR E, MODAN M, CABILI S, GAFNI J: Colchicine in the prevention and treatment of the Amyloidosis of Familial Mediterranean fever. New Engl J Med 1986;314:1001-1005.
10. TUNCA M, AKAR S, ONEN F, OZDOGAN H, KASAPCOPUR O, YALCINKAYA F, et al.; TURKISH FMF STUDY GROUP: Familial Mediterranean fever (FMF) in Turkey: results of a nationwide multicenter study. Medicine (Baltimore) 2005;84:1-11.
11. OZER FL, KAPLAMAN E, ZILELI S: Familial Mediterranean fever in Turkey. A report of twenty cases. Am J Med 1971;50:336-339.
12. ZEMER D, LIVNEH A, PRAS M, SOHAR E: The kidney in familial Mediterranean fever. Contrib Nephrol 1993;102:187-197.
13. LIVNEH A, ZEMER D, LANGEVITZ P, LAOR A, SOHAR E, PRAS M: Colchicine treatment of AA Amyloidosis of Familial Mediterranean fever. Arthritis Rheum 1994;37:1804-1811.
14. ZEMER D, LIVNEH A, LANGEVITZ P: Reversal of the nephrotic syndrome by colchicine in amyloidosis of familial Mediterranean fever. Ann Intern Med 1992;116:426.
15. CAKAR N, YALçINKAYA F, OZKAYA N et al.: Familial Mediterranean fever (FMF)-associated amyloidosis in childhood. Clinical features, course and outcome. Clin Exp Rheumatol 2001;19(Suppl. 24):S63-S67.
16. GILLMORE JD, LOVAT LB, PERSEY MR, PEPYS MB, HAWKINS PN: Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001;358:24-29.
17. DEMBER LM: Amyloid-associated kidney disease. J Am Soc Nephrol 2006;17:3458-3471.
18. GOTTENBERG JE, MERLE-VINCENT F, BENTABERRY F et al.: Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a follow-up report of tolerability and efficacy. Arthritis Rheum 2003;48:2019-2024.
19. OZTURK MA, KANBAY M, KASAPOGLU B et al.: Therapeutic approach to familial Mediterranean fever: a review update. Clin Exp Rheumatol 2011;29(Suppl. 67):S77-S86.
20. ONER A, ERDOGAN O, DEMIRCIN G, BULBUL M, MEMIS L: Efficacy of colchicine therapy in amyloid nephropathy of familial Mediterranean fever. Pediatr Nephrol 2003;18:521-526.
21. OBICI L, RAIMONDI S, LAVATELLI F, BELLOTTI V, MERLINI G: Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview. Arthritis Rheum 2009;61:1435-1440.
22. CHAE JJ, WOOD G, MASTERS SL et al.: The B30.2 domain of pyrin, the familial Mediterranean fever protein, interacts directly with caspase-1 to modulate IL-1beta production. Proc Natl Acad Sci USA 2006;103:9982-9987.
23. KORKMAZ C: Immunosuppressive treatment of AA amyloidosis of familial Mediterranean fever. Clin Exp Rheumatol 2005;23(Suppl.38):S107-S108.
24. SAYARLIOGLU H, ERKOC R, SAYARLIOGLU M, DOGAN E, SOYORAL Y: Successful treatment of nephrotic syndrome due to FMF amyloidosis with azathioprine: report of three Turkish cases. Rheumatol Int 2006;27:197-199.
25. NAKAMURA T, YAMAMURA Y, TOMODA K, TSUKANO M, SHONO M, BABA S: Efficacy of cyclophosphamide combined with prednisolone in patients with AA amyloidosis secondary to rheumatoid arthritis. Clin Rheumatol 2003;22:371-375.
26. SHAPIRO M, ZALEWSKI S, STEINER Z et al.: Adrenal insufficiency in a general hospital over a 14-year period. Isr J Med Sci 1984;20:381-387.
27. KORKMAZ C, COLAK O, ALATAS O, OZARSLAN A, ERGüL B: Early blunted cortisol response to insulin induced hypoglycaemia in familial Mediterranian fever. Clin Exp Rheumatol 2002;20(Suppl. 26):S8-S12.
28. METYAS S, ARKFELD DG, FORRESTER DM, EHRESMANN GR: Infliximab treatment of Familial Mediterranean fever and its effect on secondary AA amyloidosis. J Clin Rheumatol 2004;10:134-137.
29. YüKSEL S, YALçINKAYA F, ACAR B, öZçAKAR ZB, öZTüRK B, EKIM M: Clinical improvement with infliximab in a child with amyloidosis secondary to familial Mediterranean fever. Rheumatology 2006;45:1307-1308.
30. OZGOCMEN S, AKGUL O: Anti-TNF agents in familial Mediterranean fever: report of three cases and review of the literature. Mod Rheumatol 2011;21:684-690.
31. ERTEN S, ERTEN SF, ALTUNOGLU A: Successful treatment with anti-tumor necrosis factor (anti-TNF)-alpha of proteinuria in a patient with familial mediterranean fever (FMF) resistant to colchicine: anti-TNF drugs and FMF. Rheumatol Int 2012;32:1095-1097.
32. öZCAKAR ZB, YüKEL S, EKIM M, YALçINKAYA F: Infliximab therapy for familial Mediterranean fever-related amyloidosis: case series with long term follow-up. Clin Rheumatol 2012;31:1267-1271.
33. BILGINER Y, AYAZ NA, OZEN S: Anti-IL-1 treatment for secondary amyloidosis in an adolescent with FMF and Behçet's disease. Clin Rheumatol 2010;29:209-210.
34. STANKOVIC STOJANOVIC K, DELMAS Y, TORRES PU et al.: Dramatic beneficial effect of interleukin-1 inhibitor treatment in patients with familial Mediterranean fever complicated with amyloidosis and renal failure. Nephrol Dial Transplant 2012;27:1898-1901.
35. VANDECASTEELE SJ, DE PAEPE P, DE VRIESE AS: Successful treatment of renal AA amyloidosis in familial Mediterranean fever with pegylated alpha-2a interferon. Clin Nephrol 2011;75(Suppl. 1):1-3.
36. OKUDA Y, TAKASUGI K: Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. Arthritis Rheum 2006;54:2997-30002.
37. DEMBER LM, HAWKINS PN, HAZENBERG BP, GOREVIC PD, MERLINI G, BUTRIMIENE I, EPRODISATE FOR AA AMYLOIDOSIS TRIAL GROUP: Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007;356:2349-2360.
38. PETTERSSON T, KONTTINEN YT, MAURY CP: Treatment strategies for amyloid A amyloidosis. Expert Opin Pharmacother 2008;9:2117-2128.